Welcome to our dedicated page for Lionsgate studios SEC filings (Ticker: LION), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lionsgate Studios Corp. (NYSE: LION) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a British Columbia–incorporated, NYSE‑listed studio business. These documents offer detailed insight into its motion picture and television production operations, capital structure and governance.
Annual reports (Form 10‑K) and quarterly reports (Form 10‑Q) present consolidated financial statements, segment information for the Motion Picture and Television Production businesses, management’s discussion and analysis, and discussions of liquidity, corporate debt and film‑related obligations. Investors can review how Lionsgate reports studio revenue, operating results, trailing 12‑month library revenue and backlog, as well as risk factors specific to its content and indebtedness profile.
Current reports on Form 8‑K include items such as earnings releases, credit facility amendments and shareholder meeting announcements. For example, Lionsgate has filed 8‑Ks describing quarterly results, amendments to the LG IP Credit Facility secured by intellectual property rights associated with library titles, and the timing and procedures for its initial annual general and special meeting of shareholders.
Registration statements, including the company’s amended Form S‑1, explain the separation of the studio business from the STARZ‑branded subscription platform, the listing of Lionsgate Studios Corp. shares on the NYSE under the symbol LION, and detailed information on capital stock, governance, executive and director compensation and risk factors.
Through Stock Titan, users can see new Lionsgate filings as they are made available via EDGAR and access AI‑generated summaries that highlight key points in lengthy documents. These summaries can help readers quickly understand complex sections on topics such as material indebtedness, film‑related obligations, shareholder rights and segment performance, while still allowing direct review of the full filings for deeper analysis.
Registration of 208,122 Common Shares — This Prospectus Supplement registers 208,122 common shares related to exercises of options and stock appreciation rights issued under the Lionsgate Studios Corp. 2025 Performance Incentive Plan. It supplements the Prospectus dated August 5, 2025 and attaches a Form 8-K filed April 15, 2026.
The Form 8-K discloses a First Amendment to CEO Jon Feltheimer’s employment agreement: the term is extended through July 31, 2031, and he was granted a 4,500,000-option award (exercise price $11.07) and 666,667 RSUs in three performance-and-service vesting tranches with stock-price hurdles of $17.50, $20.00 and $22.50 (each measured by a 20-day average) and five-year performance periods. The supplement notes the last reported NYSE sale price was $11.09 per share on April 14, 2026.
Lionsgate Studios Corp. Chief Executive Officer Jon Feltheimer received a compensation package made up of stock options and restricted share units tied to future share-price performance and continued employment.
He was granted 4,500,000 non-qualified stock options with an exercise price of $11.07 per share, expiring on April 13, 2036. These options vest in three tranches only if specific stock price goals are reached within five years and he remains employed through the fifth anniversary or experiences an earlier involuntary termination. The goals are $17.50 for 2,500,000 shares, $20.00 for 1,000,000 shares, and $22.50 for 1,000,000 shares, based on a 20-day average closing price.
Feltheimer also received 666,667 restricted share units (RSUs), each convertible into one common share upon vesting. These RSUs have similar five-year, employment-based vesting conditions and three stock price hurdles: $17.50 for 370,371 RSUs, $20.00 for 148,148 RSUs, and $22.50 for 148,148 RSUs, measured over twenty consecutive trading days.
Lionsgate Studios Corp. amended Chief Executive Officer Jon Feltheimer’s employment agreement, extending its term by two years to July 31, 2031 and adding new performance-based equity incentives.
Feltheimer is granted options to purchase up to 4,500,000 common shares at an exercise price of $11.07 per share and 666,667 restricted share units, split into three tranches. Each tranche vests only if specific stock price goals of $17.50, $20.00 and $22.50 are achieved within five years and if he remains employed through the fifth anniversary, subject to certain termination protections.
The agreement maintains an annual base salary of $1,500,000, a target annual bonus of $7,500,000 with a 200% maximum, and long-term incentive grants targeted at $10,000,000 per year for fiscal years 2026 through 2029, along with detailed severance and change-in-control protections.
Lionsgate Studios Corp. General Counsel Tobey Bruce reported a routine tax-withholding share disposition tied to vesting equity awards. The company withheld 11,637 common shares at $10.45 per share to cover taxes when 22,872 restricted share units vested. After this automatic cancellation, Bruce beneficially owns 285,497 common shares, including multiple blocks of RSUs scheduled to vest between July 2026 and July 2028.
FINE EMILY reported acquisition or exercise transactions in this Form 4 filing.
Lionsgate Studios Corp. director Emily Fine received an equity grant of 5,252 Common Shares on April 1, 2026. The shares were awarded as director fees valued at $9.52 per share, reflecting compensation rather than an open-market purchase.
Following this award, Fine directly holds 136,788 Common Shares. Footnotes explain the grant relates to restricted share units that are payable in an equal number of Common Shares and are scheduled to vest in a remaining annual installment on November 28, 2026.
RACHESKY MARK H MD reported acquisition or exercise transactions in this Form 4 filing.
Lionsgate Studios Corp. director and 10% owner Mark H. Rachesky, M.D. received a stock-based director fee grant of 7,983 Common Shares at $9.52 per share. The award increased his directly held stake to 259,471 Common Shares as of April 1, 2026.
He also reports substantial additional Common Shares held indirectly through multiple MHR-managed investment funds, where various MHR entities and Dr. Rachesky may be deemed beneficial owners but disclaim beneficial ownership beyond their pecuniary interest. In addition, restricted share units are scheduled to vest into an equal number of Common Shares in a remaining annual installment on November 28, 2026.
Rosenblatt M Richard reported acquisition or exercise transactions in this Form 4 filing.
Lionsgate Studios Corp. director M. Richard Rosenblatt received a grant of 5,252 common shares on April 1, 2026, recorded as director fees paid in stock at an indicated price of $9.52 per share. After this award, he directly holds 60,797 common shares, plus 20,107 restricted share units that are scheduled to vest on November 28, 2026, each RSU payable in one common share upon vesting.
Ostolaza Yvette reported acquisition or exercise transactions in this Form 4 filing.
Lionsgate Studios Corp. director Yvette Ostolaza received a grant of 6,303 common shares on a compensation basis, valued at $9.52 per share. This was classified as a grant or award, not an open-market purchase.
After this award, she directly holds 147,820 common shares. Her holdings also include 20,107 restricted share units granted by the company, which are scheduled to vest on November 28, 2026, and will be payable in an equal number of common shares upon vesting.
SLOAN HARRY reported acquisition or exercise transactions in this Form 4 filing.
Lionsgate Studios Corp. director Harry Sloan received a grant of 6,828 common shares on April 1, 2026 as director fees, valued at $9.52 per share. Following this award, he directly holds 415,913 common shares, including 20,107 restricted share units scheduled to vest on November 28, 2026.
HARKEY JOHN D JR reported acquisition or exercise transactions in this Form 4 filing.
Lionsgate Studios Corp. director John D. Harkey Jr. received a grant of 6,828 common shares as part of his director fees, valued at $9.52 per share. This is a compensation-related award rather than an open-market purchase.
After this grant, he directly holds 208,188 common shares, including 20,107 restricted share units that are scheduled to vest on November 28, 2026, and will be settled in an equal number of common shares.